Freeline Therapeutics Holdings plc Quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax in USD from Q4 2019 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.
Summary
Freeline Therapeutics Holdings plc quarterly Accumulated Other Comprehensive Income (Loss), Net of Tax history and growth rate from Q4 2019 to Q3 2023.
  • Freeline Therapeutics Holdings plc Accumulated Other Comprehensive Income (Loss), Net of Tax for the quarter ending September 30, 2023 was -$1.57M, a 82.3% increase year-over-year.
Accumulated Other Comprehensive Income (Loss), Net of Tax, Quarterly (USD)
Accumulated Other Comprehensive Income (Loss), Net of Tax, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2023 -$1.57M +$7.29M +82.3% Sep 30, 2023 6-K 2023-12-01
Q2 2023 -$784K +$712K +47.6% Jun 30, 2023 6-K 2023-08-15
Q1 2023 -$1.72M -$8.46M -125% Mar 31, 2023 6-K 2023-05-30
Q4 2022 -$3.15M -$12.6M -133% Dec 31, 2022 6-K 2023-12-01
Q3 2022 -$8.85M -$17.9M -198% Sep 30, 2022 6-K 2022-11-15
Q2 2022 -$1.5M -$15.7M -111% Jun 30, 2022 6-K 2022-08-09
Q1 2022 $6.74M -$4.63M -40.7% Mar 31, 2022 6-K 2022-05-10
Q4 2021 $9.47M +$130K +1.39% Dec 31, 2021 20-F 2023-04-04
Q3 2021 $9.06M Sep 30, 2021 6-K 2021-11-09
Q2 2021 $14.2M +$21.4M Jun 30, 2021 6-K 2021-08-16
Q1 2021 $11.4M Mar 31, 2021 6-K 2021-05-17
Q4 2020 $9.34M +$12.3M Dec 31, 2020 20-F 2022-03-31
Q2 2020 -$7.17M Jun 30, 2020 6-K 2020-10-29
Q4 2019 -$3M Dec 31, 2019 20-F 2021-03-31
* An asterisk sign (*) next to the value indicates that the value is likely invalid.